PTX News Alert Pernix Therapeutics Holdings Inc. (PTX) 8.63 02/13/2015

New Post Public Reply Private Reply Replies (0) Message Board

Feb 13, 2015 at 11:58 PM

Pernix Therapeutics Holdings Inc. (PTX) 8.63 $PTX

Pernix Therapeutics (PTX) Stock Gaining Today After Cantor Fitzgerald Initiates Coverage
at The Street - Tue Feb 10, 10:43AM CST
Shares of Pernix Therapeutics (PTX) are up after Cantor Fitzgerald initiated the company with a 'buy' rating and a $11 price target.
PTX: 8.63 (+0.01)

The Long Case For Pernix
ONeil Trader - at Seeking Alpha - Thu Jan 22, 8:37AM CST

PTX: 8.63 (+0.01)

CORRECTING and REPLACING Pernix Therapeutics Exceeds 2014 Revenue Guidance: Delivers FY2014 Net Revenue In Excess of $120 Million
Business Wire - Tue Jan 20, 9:14AM CST
Subhead of release should read: Company to host a Conference Call and Webcast on Wednesday, February 25th beginning at 10:00 a.m. EST to report 4Q and FY2014 Financial Results (instead of Monday, February 25th).
PTX: 8.63 (+0.01)

Pernix preliminary Q4 revenues up 117%
Seeking Alpha - at Seeking Alpha - Tue Jan 20, 8:22AM CST

PTX: 8.63 (+0.01)

Pernix Therapeutics Exceeds 2014 Revenue Guidance: Delivers FY2014 Net Revenue In Excess of $120 Million
Business Wire - Tue Jan 20, 7:31AM CST
Pernix Therapeutics Holdings, Inc. (NASDAQ

TX), a specialty pharmaceutical company, today announced that based on a preliminary review of 2014 fourth quarter results it expects Net Revenue to exceed FY2014 guidance. The Company's preliminary results remain subject to finalization by its management and audit by its independent registered public accounting firm. The Company plans to report final results for the fourth quarter and full year 2014 on February 25 2015.
PTX: 8.63 (+0.01)

FDA accepts Pernix's application for Treximet expanded label
Seeking Alpha - at Seeking Alpha - Thu Jan 15, 2:56PM CST

PTX: 8.63 (+0.01)

Pernix Therapeutics Announces FDA Acceptance With Priority Review of Its TREXIMET(R) sNDA for Use in Adolescent Patients
Business Wire - Thu Jan 15, 2:41PM CST
Pernix Therapeutics Holdings, Inc. (NASDAQ

TX) today announced that its supplemental New Drug Application (sNDA) for TREXIMET (sumatriptan / naproxen sodium) has been accepted by the U.S. Food and Drug Administration (FDA). Approval is expected in 2Q 2015, based on the anticipated Prescription Drug User Fee Act (PDUFA) action date.
PTX: 8.63 (+0.01)

Commit To Purchase Pernix Therapeutics Holdings At $7.50, Earn 27.7% Annualized Using Options
at The Street - Mon Jan 12, 10:39AM CST
Investors considering a purchase of Pernix Therapeutics Holdings, Inc. stock, but cautious about paying the going market price of $8.77/share, might benefit from considering selling puts among the alternative strategies at their disposal.
PTX: 8.63 (+0.01)

Nasdaq makes annual changes to Biotechnology Index
Seeking Alpha - at Seeking Alpha - Mon Dec 15, 11:36AM CST

TTPH: 35.18 (-0.73), ZSPH: 46.77 (+3.42), AMRN: 1.18 (unch), OPHT: 51.11 (+0.12), AERI: 27.91 (+0.14), ASPX: 65.76 (+2.76), CNCE: 12.76 (-0.46), ICEL: 5.27 (+0.02), GWPH: 78.09 (+1.70), AUXL: 36.47 (-0.06), RTRX: 13.92 (+0.44), RCPT: 115.83 (-0.66), AAVL: 36.29 (+0.01), AKBA: 9.32 (+0.51), EXPR: 14.61 (+0.33), RARE: 54.10 (+0.12), RLYP: 33.98 (+0.60), PETX: 16.52 (-0.10), ENTA: 33.30 (-0.44), RDUS: 50.37 (+0.63), CARA: 10.96 (-0.03), FLML: 14.15 (+0.15), ALIM: 5.16 (unch), ANIP: 62.69 (-0.43), ICPT: 209.12 (+7.12), RVNC: 16.84 (+0.27), POZN: 6.95 (+0.15), FPRX: 24.63 (+0.63), ZFGN: 39.06 (+0.92), CRIS: 3.23 (+0.25), QLTI: 4.15 (unch), PCYC: 163.28 (+0.23), PTX: 8.63 (+0.01), CLDN: 16.45 (-0.05), RIGL: 2.47 (+0.05), HPTX: 26.83 (-0.05), AMPH: 12.76 (+0.02), INO: 6.80 (-0.15), VSAR: 18.04 (-0.55), FMI: 48.88 (+0.17), TBPH: 18.51 (+0.28), XLRN: 38.02 (+0.07), MGNX: 34.09 (+0.10), INSM: 17.40 (+0.69), ONTX: 2.27 (-0.02), ALDR: 26.06 (+0.18), SAGE: 41.03 (-0.07), KITE: 62.59 (+0.82), CGEN: 8.19 (+0.08), FOLD: 8.36 (-0.11), KPTI: 27.12 (-0.13)

Annual Changes to the NASDAQ Biotechnology Index
GlobeNewswire - Mon Dec 15, 6:10AM CST
The NASDAQ OMX Group, Inc. (Nasdaq:NDAQ) today announced the results of the annual re-ranking of the NASDAQ Biotechnology Index (Nasdaq:NBI), which will become effective prior to market open on Monday, December 22, 2014.
TTPH: 35.18 (-0.73), ZSPH: 46.77 (+3.42), AMRN: 1.18 (unch), OPHT: 51.11 (+0.12), AERI: 27.91 (+0.14), ASPX: 65.76 (+2.76), CNCE: 12.76 (-0.46), ICEL: 5.27 (+0.02), GWPH: 78.09 (+1.70), AUXL: 36.47 (-0.06), RTRX: 13.92 (+0.44), RCPT: 115.83 (-0.66), AAVL: 36.29 (+0.01), AKBA: 9.32 (+0.51), EXPR: 14.61 (+0.33), RARE: 54.10 (+0.12), ZGNX: 1.43 (+0.05), RLYP: 33.98 (+0.60), PETX: 16.52 (-0.10), ENTA: 33.30 (-0.44), RDUS: 50.37 (+0.63), CARA: 10.96 (-0.03), FLML: 14.15 (+0.15), ALIM: 5.16 (unch), ANIP: 62.69 (-0.43), ICPT: 209.12 (+7.12), RVNC: 16.84 (+0.27), POZN: 6.95 (+0.15), NDAQ: 49.48 (-0.27), FPRX: 24.63 (+0.63), CRIS: 3.23 (+0.25), ZFGN: 39.06 (+0.92), QLTI: 4.15 (unch), PCYC: 163.28 (+0.23), PTX: 8.63 (+0.01), CLDN: 16.45 (-0.05), RIGL: 2.47 (+0.05), HPTX: 26.83 (-0.05), AMPH: 12.76 (+0.02), INO: 6.80 (-0.15), VSAR: 18.04 (-0.55), FMI: 48.88 (+0.17), TBPH: 18.51 (+0.28), XLRN: 38.02 (+0.07), MGNX: 34.09 (+0.10), INSM: 17.40 (+0.69), ONTX: 2.27 (-0.02), ALDR: 26.06 (+0.18), SAGE: 41.03 (-0.07), KITE: 62.59 (+0.82), CGEN: 8.19 (+0.08), FOLD: 8.36 (-0.11), KPTI: 27.12 (-0.13)

Pernix Therapeutics Inc. to Present at the Oppenheimer Healthcare Conference in New York, NY
Business Wire - Mon Dec 01, 7:00AM CST
Pernix Therapeutics Holdings, Inc. (NASDAQ

TX), a specialty pharmaceutical company, announced today that Doug Drysdale, Chairman, President and Chief Executive Officer and Sanjay Patel, Chief Financial Officer, are scheduled to present at the Oppenheimer Healthcare conference in NYC on December 11, 2014.
PTX: 8.63 (+0.01)

Pernix Therapeutics Inc. to Present at the 26th Annual Piper Jaffray Healthcare Conference
Business Wire - Mon Nov 24, 7:37AM CST
Pernix Therapeutics Holdings, Inc. (NASDAQ: PTX), a specialty pharmaceutical company, announced today that Douglas Drysdale, Chairman, President and Chief Executive Officer and Sanjay Patel, Chief Financial Officer, are scheduled to present at the Annual Piper Jaffray Healthcare Conference in New York, NY on December 2, 2014.
PTX: 8.63 (+0.01)

Pernix Submits sNDA for TREXIMET(R) Use in Adolescent Patients
Business Wire - Mon Nov 17, 6:39AM CST
Pernix Therapeutics Holdings, Inc. (NASDAQ

TX) today announced the submission of a supplemental New Drug Application (sNDA) to the U.S. Food and Drug Administration (FDA) for TREXIMET (sumatriptan / naproxen sodium) to seek approval for use in adolescent patients, age 12 - 17, for the acute treatment of migraine with or without aura.
PTX: 8.63 (+0.01)

Nasdaq stocks posting largest percentage increases
AP - Tue Nov 11, 12:52PM CST
NEW YORK (AP) — A look at the 10 biggest percentage gainers on Nasdaq at 1 p.m.:
PGNX: 5.66 (+0.06), ICUI: 88.98 (+0.42), CDZI: 10.09 (+0.22), INSY: 51.50 (-0.66), PCMI: 9.21 (+0.20), PTX: 8.63 (+0.01), CYAN: 8.72 (+0.13), ACHN: 10.89 (-0.20), AGIO: 118.55 (+0.11), LIOX: 5.57 (+0.10), PLNR: 6.63 (-0.07)

Midday gainers / Losers
Seeking Alpha - at Seeking Alpha - Tue Nov 11, 11:45AM CST

FSM: 4.56 (+0.03), HEAR: 2.54 (-0.14), JRJC: 5.46 (+0.16), CVO: 1.92 (-0.04), AAOI: 10.15 (-0.05), UNIS: 4.32 (+0.06), HIIQ: 8.03 (+0.16), CYAN: 8.72 (+0.13), PTX: 8.63 (+0.01), TRMR: 2.15 (+0.04), PRKR: 1.07 (+0.04), SUMR: 2.91 (+0.02), VSLR: 8.39 (+0.06), RVP: 5.14 (-0.42), ASCMA: 47.45 (+0.25), ICUI: 88.98 (+0.42), CALL: 7.74 (+0.02), DMD: 5.13 (+0.10), AST: 3.85 (+0.13), ASEI: 56.82 (+0.30)

Pernix Therapeutics Holdings' (PTX) CEO Douglas Drysdale on Q3 2014 Results - Earnings Call Transcript
SA Transcripts - at Seeking Alpha - Mon Nov 10, 2:46PM CST

PTX: 8.63 (+0.01)

Pernix Therapeutics ups revenues 72% in Q3
Seeking Alpha - at Seeking Alpha - Mon Nov 10, 12:15PM CST

PTX: 8.63 (+0.01)

Pernix Therapeutics Holdings (PTX) Q3 2014 Results - Earnings Call Webcast
SA Transcripts - at Seeking Alpha - Mon Nov 10, 8:55AM CST

PTX: 8.63 (+0.01)

Pernix Therapeutics misses by $0.02, beats on revenue
Seeking Alpha - at Seeking Alpha - Mon Nov 10, 7:09AM CST

PTX: 8.63 (+0.01)

Pernix Therapeutics Reports Third Quarter 2014 Financial Results and Reaffirms Guidance
Business Wire - Mon Nov 10, 7:01AM CST
--Company Reiterates Full Year 2014 and 2015 Guidance
PTX: 8.63 (+0.01)

Newer

Older

Scroll down for more posts ▼

Top 10 Most Recent News Articles

Moore Law Urges Millrose Investors: Join the Action

Is Millrose Playing a Risky Game? When I caught wind of this latest debacle with Millrose Properties, Inc. (NYSE: MRP), my gut reaction was a mix of curiosity and skepticism. Hunterbrook Media's report just blasted across the headlines, digging up some dirt on Millrose's recent financial maneuvers. Apparently, these cats have been busy buying homes to the tune of $200...

Alpha Rising Joins RFP: A Strong AI-Fueled Expansion

The Shift: From LPL to AI-Driven Innovation Hold onto your hats, because Alpha Rising Wealth Management has taken a significant leap from the traditional ship of LPL Financial to the cutting-edge shores of Rothschild Financial Partners (RFP). It's a move that's painting the walls in Scottsdale, Arizona with $250 million in client assets, all set to benefit from a modern,...

JELD-WEN CFO Transition: Navigating Finances Amid Changes

Leadership Shake-up at JELD-WEN Alright, folks, the boardroom saga over at JELD-WEN just took another spin. Samantha Stoddard, the brain behind the numbers as Chief Financial Officer, is packing her bags come mid-November. Yeah, she's off to chase new horizons outside the realm of building products, leaving a spot hotter than a New York Stock Exchange ring bell up for...

Baidu Faces Class Action: Investors Push Against Fraud Allegations

Baidu Under Fire for Alleged Misleading Statements Here's a fresh slice of drama straight outta the corporate trenches: Baidu, Inc. (NASDAQ: BIDU) finds itself tangled in a securities fraud lawsuit that’s causing a ruckus across investor circles. Schall, Brown & Schwartz LLP, those heavyweight gladiators in shareholder rights, are calling on grieved investors to step up...

Understanding Truck Accident Settlements in Memphis

Delving into Truck Accident Settlement Timelines Out there in Memphis, timing a truck accident settlement isn't exactly like clockwork work. When it comes to getting your compensation, the timeline varies as widely as a duck hunting trip—sometimes you come home with a basketful, sometimes it’s empty. It might be a quick couple of months or drag on past a year, and...

Chemours Faces Investor Fraud Suit: Action Needed Now

A Messy Situation Unfolds for Chemours Company You know, stumbling upon a battle scene like this isn't something I enjoy, but here we have Chemours Company (NYSE: CC) embroiled in a securities fraud lawsuit. It's like catching wind of a brawl outside your favorite tavern—can't ignore it, can you? The Lawsuit's Crux and Key Dates to Watch Here's the rundown. The fight...

Angels on Call Sets Benchmark for Specialized Homecare

Pioneering a New Standard in Homecare Take a gander at Angels on Call Homecare. They're not just another name in a crowded field; they've carved out a niche—specializing in elite care for Dementia and Parkinson's patients. You don't usually hear homecare and innovation in the same breath, do you? But these folks are setting a fresh benchmark. Independent feedback has...

AppLovin Faces Securities Fraud Lawsuit Amid AI Claims

Digging Into AppLovin's Legal Turmoil Well, it's another wrinkle in the markets' many lines. This time, we’ve got AppLovin Corporation facing the music with a securities fraud lawsuit. If you’ve got shares in NASDAQ:APP, you might want to perk up. Let the trial by fire begin, I say. The Lawsuit Details & Class Period Here we are, October 19, 2026, and the legal eagles...

Roof Inspections: Richmond's Key to Home Longevity

Inspect, Protect, and Forget Your Worries Homeowners in the Greater Richmond area wisely take to heart the old saying: an ounce of prevention is worth a pound of cure. But let's cut through the noise for a moment and zero in on a foundational truth: regular roof inspections are not a luxury—they're an absolute must. Roofing expert Seth Brown, from BNH Roofing, makes it...

Workday Hits High Note in 2026 Gartner Magic Quadrant

Workday Secures Leadership Position In a wild ride that's left investors with whiplash in recent years, Workday (NASDAQ: WDAY) has firmly planted its flag at the top tier of the 2026 Gartner® Magic Quadrant™ for Cloud ERP Finance. This announcement out of Pleasanton, California, resonates like a victory bell for the company's finance management solutions—a mix of AI,...